title: A new approach for cellular immunotherapy of nasopharyngeal carcinoma.
abstract: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been developed to rapidly generate high frequency EBV-specific T cells to treat patients with refractory or metastatic disease.
authors.affiliation: Australian Centre for Vaccine Development and Tumour Immunology Laboratory; Department of Immunology; Queensland Institute of Medical Research; Brisbane, Australia.
authors.forename: Corey
authors.initials: C
authors.lastname: Smith
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khanna